Human Genetics, GlaxoSmithKline R&D, Medicines Research Centre, Gunnels Wood Road, Stevenage, SG1 2NY, UK.
Functional Genomics, GlaxoSmithKline R&D, Collegeville, PA, USA.
BMC Microbiol. 2021 Jun 15;21(1):181. doi: 10.1186/s12866-021-02245-8.
With increasing concerns about the impact of frequent antibiotic usage on the human microbiome, it is important to characterize the potential for such effects in early antibiotic drug development clinical trials. In a randomised Phase 2a clinical trial study that evaluated the pharmacokinetics of repeated oral doses of gepotidacin, a first-in-chemical-class triazaacenaphthylene antibiotic with a distinct mechanism of action, in adult females with uncomplicated urinary tract infections for gepotidacin (GSK2140944) we evaluated the potential changes in microbiome composition across multiple time points and body-sites ( ClinicalTrials.gov : NCT03568942).
Samples of gastrointestinal tract (GIT), pharyngeal cavity and vaginal microbiota were collected with consent from 22 patients at three time points relative to the gepotidacin dosing regimen; Day 1 (pre-dose), Day 5 (end of dosing) and Follow-up (Day 28 ± 3 days). Microbiota composition was determined by DNA sequencing of 16S rRNA gene variable region 4 amplicons. By Day 5, significant changes were observed in the microbiome diversity relative to pre-dose across the tested body-sites. However, by the Follow-up visit, microbiome diversity changes were reverted to compositions comparable to Day 1. The greatest range of microbiome changes by body-site were GIT followed by the pharyngeal cavity then vagina. In Follow-up visit samples we found no statistically significant occurrences of pathogenic taxa.
Our findings suggest that gepotidacin alteration of the human microbiome after 5 days of dosing is temporary and rebound to pre-dosing states is evident within the first month post-treatment. We recommend that future antibiotic drug trials include similar exploratory investigations into the duration and context of microbiome modification and recovery.
NCT03568942 . Registered 26 June 2018.
由于人们越来越关注频繁使用抗生素对人体微生物组的影响,因此在早期抗生素药物开发临床试验中描述这种影响的潜力非常重要。在一项评估重复口服 gepotidacin(一种具有独特作用机制的首创化学类三氮杂吖辛烷抗生素)在患有单纯性尿路感染的成年女性中的药代动力学的随机 2a 期临床试验中,我们评估了在多个时间点和身体部位(ClinicalTrials.gov:NCT03568942)的微生物组组成的潜在变化。
在 gepotidacin 给药方案的三个时间点(第 1 天(预剂量)、第 5 天(结束剂量)和随访(第 28±3 天)),从 22 名患者获得了胃肠道(GIT)、咽腔和阴道微生物组样本,同意后进行收集。通过 16S rRNA 基因可变区 4 扩增子的 DNA 测序来确定微生物组组成。与预剂量相比,到第 5 天,在所有测试的身体部位中,微生物组多样性发生了显著变化。然而,在随访就诊时,微生物组多样性的变化恢复到与第 1 天相似的组成。按身体部位划分,微生物组变化范围最大的是 GIT,其次是咽腔,然后是阴道。在随访样本中,我们没有发现致病性分类群的统计学显著发生。
我们的研究结果表明,在 5 天的给药后,gpotidacin 会改变人体微生物组,并且在治疗后第一个月内,这种改变会反弹到预给药状态。我们建议,未来的抗生素药物试验应包括对微生物组修饰和恢复的持续时间和背景的类似探索性研究。
NCT03568942。于 2018 年 6 月 26 日注册。